1.Innovative Pharmaceutical Service Practice of Medical Institutes in Zhejiang Area
Jianping WANG ; Zheng SHI ; Ke MA ; Linrun WANG ; Xiaoyang LU
China Pharmacy 2016;27(1):131-133
OBJECTIVE:To provide reference further development of hospital pharmacy in China. METHODS:Innovative pharmaceutical care method of hospital pharmacy was summarized in 32 medical institutions from Zhejiang area,including 18 third-level hospitals,8 special hospitals,6 third-level TCM hospitals and integrated traditional and western medicine hospitals. RE-SULTS & CONCLUSIONS:Medical institutions provide innovative pharmaceutical service to guarantee the safety of drug use,ex-pand medical service space,enrich the connotation of pharmaceutical care,and provide reference for pharmaceutical care in medi-cal institutions of other regions,such as establishing satellite pharmacy of anesthesiology department,opening outpatient depart-ment of pharmaceutical care (elderly comprehensive evaluation and multidisciplinary outpatient pharmaceutical care,anticoagula-tion consultation outpatient department and endocrine consultation outpatient department managed by pharmacists,comprehensive pharmacy consultation outpatient department,outpatient pharmaceutical care of pharmacy unit mode),formulating pharmaceutical ward round mode under multidisciplinary cooperation,developing clinical pharmaceutical care based on pharmacy scientific re-search(drug monitor,gene detection)and evidence-based medicine.
2.Roles of protein tyrosine phosphatase SHP2 in lung cancer
Lingjuan HE ; Hongqiang CHENG ; Yuehai KE ; Linrun WANG
Chinese Journal of Pharmacology and Toxicology 2016;(1):82-86
The reversible phosphorylation plays an important regulatory role in various pathological and physiological processes. Src Homology 2 domain containing protein tyrosine phosphatase (SHP2),a featured member of the protein tyrosine phosphatase family,is identified as the first PTP proto-oncogene. SHP2 is associated with breast cancer,leukemia,lung cancer,liver cancer,gastric cancer,laryngeal cancer,oral cancer and other types of cancer. Signalling pathways involving SHP2 have also been discovered. It has been recently reported that the high expression of SHP2 in lung cancer regulates cancer cell proliferation,metastasis and drug resistance. SHP2 may be a potential thera?peutic target because it is implicated in many diseases. This article focuses on the research progress in functions of SHP2 in lung cancer.